ProKidney Corp. (NASDAQ:PROK) Shares Acquired by Federated Hermes Inc.

Federated Hermes Inc. raised its position in shares of ProKidney Corp. (NASDAQ:PROK) by 10,984.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 113,286 shares of the company’s stock after purchasing an additional 112,264 shares during the period. Federated Hermes Inc.’s holdings in ProKidney were worth $202,000 at the end of the most recent quarter.

Separately, SG Americas Securities LLC acquired a new position in ProKidney during the 3rd quarter valued at about $78,000. 51.59% of the stock is owned by institutional investors.

ProKidney Stock Up 2.3 %

ProKidney stock opened at $2.20 on Monday. The firm has a 50-day moving average price of $1.79 and a two-hundred day moving average price of $1.67. The firm has a market capitalization of $504.55 million, a price-to-earnings ratio of -3.86 and a beta of 0.78. ProKidney Corp. has a 52-week low of $1.12 and a 52-week high of $13.51.

ProKidney (NASDAQ:PROK) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Research analysts expect that ProKidney Corp. will post -0.65 earnings per share for the current year.

Insider Transactions at ProKidney

In other news, SVP Darin J. Weber sold 17,238 shares of the company’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $2.50, for a total value of $43,095.00. Following the completion of the sale, the senior vice president now directly owns 172,432 shares of the company’s stock, valued at approximately $431,080. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, SVP Darin J. Weber sold 84,103 shares of the business’s stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $1.73, for a total value of $145,498.19. Following the sale, the senior vice president now directly owns 189,670 shares in the company, valued at approximately $328,129.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Darin J. Weber sold 17,238 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $2.50, for a total transaction of $43,095.00. Following the completion of the sale, the senior vice president now owns 172,432 shares in the company, valued at $431,080. The disclosure for this sale can be found here. In the last three months, insiders sold 118,879 shares of company stock valued at $232,392. Company insiders own 44.99% of the company’s stock.

Analyst Ratings Changes

Separately, Morgan Stanley initiated coverage on shares of ProKidney in a research note on Thursday, March 7th. They set an “equal weight” rating and a $3.00 target price for the company.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.